Synermore Biologics (Suzhou) Co., Ltd.
Synermore Biologics, invested by SINOVAC, is a leading Chinese biopharmaceutical innovation company dedicated to eliminating human diseases through the development, production, and sales of innovative monoclonal antibody drugs and biosimilars. The company focuses on malignant tumors, autoimmune diseases, and infectious diseases, establishing a complete industrial chain for humanized monoclonal antibody drugs. With a global outlook, a rich product pipeline, and extensive patent protection, Synermore aims to become an internationally competitive and influential biopharmaceutical enterprise.
Industries
Nr. of Employees
small (1-50)
Synermore Biologics (Suzhou) Co., Ltd.
Building 5, No. 218, Sangtian Street, Suzhou Industrial Park, Jiangsu Province, 215000
Patents
Antibody specific to alpha-toxin of Staphylococcal aureus and uses thereof
US-11530256-B2
View Details
Antibody specific to alpha-toxin of Staphylococcal aureus and uses thereof
US-11530256-B2
View DetailsProducts
Monoclonal antibody cocktail injection for rabies post‑exposure prophylaxis
A marketed Class I innovative monoclonal antibody cocktail formulated for passive immunization of adults exposed to rabies virus; positioned as an alternative to rabies immune globulin.
Investigational monoclonal antibodies and biosimilars
Pipeline of investigational therapeutics including antibodies targeting bacterial toxins and lytic enzymes, an investigational therapeutic enzyme, and biosimilar programs corresponding to established reference biologics.
Monoclonal antibody cocktail injection for rabies post‑exposure prophylaxis
A marketed Class I innovative monoclonal antibody cocktail formulated for passive immunization of adults exposed to rabies virus; positioned as an alternative to rabies immune globulin.
Investigational monoclonal antibodies and biosimilars
Pipeline of investigational therapeutics including antibodies targeting bacterial toxins and lytic enzymes, an investigational therapeutic enzyme, and biosimilar programs corresponding to established reference biologics.
Services
End-to-end R&D for therapeutic monoclonal antibodies and biologics, from design and expression to preclinical and clinical development.
cGMP-compliant production capabilities including large-scale bioreactor capacity and established QA/QC systems for clinical and commercial supply.
Operational adverse event intake and reporting process, with contact channels (telephone and email) for reporting and follow-up.
End-to-end R&D for therapeutic monoclonal antibodies and biologics, from design and expression to preclinical and clinical development.
cGMP-compliant production capabilities including large-scale bioreactor capacity and established QA/QC systems for clinical and commercial supply.
Operational adverse event intake and reporting process, with contact channels (telephone and email) for reporting and follow-up.
Expertise Areas
- Monoclonal antibody R&D and humanization
- Biosimilar development
- Biologics process development and scale-up
- cGMP biologics manufacturing
Key Technologies
- Monoclonal antibody engineering
- Antibody humanization
- Recombinant expression systems
- Upstream bioprocessing (large‑scale cell culture)
News & Updates
In May 2022, the company submitted an NDA application for Zamerovimab and Mazorelvimab in China.
In June 2024, the products received approval for marketing in China.
A Phase III clinical study of Kreybi was published in the Vaccine journal, demonstrating its efficacy and safety.
Cao Yifu, CEO of Synermore, was invited to present at the Vaccines 2025 conference in the Netherlands.
Company's Zamerovimab and Mazorelvimab injection recognized as Suzhou Innovative Famous and Excellent Product
In 2024, the company's product received recognition as an innovative product in Suzhou.
Company recognized as Jiangsu Innovative Small and Medium-sized Enterprise
In 2024, the company was recognized as an innovative SME in Jiangsu Province.
In May 2022, the company submitted an NDA application for Zamerovimab and Mazorelvimab in China.
In June 2024, the products received approval for marketing in China.
A Phase III clinical study of Kreybi was published in the Vaccine journal, demonstrating its efficacy and safety.
Cao Yifu, CEO of Synermore, was invited to present at the Vaccines 2025 conference in the Netherlands.
Company's Zamerovimab and Mazorelvimab injection recognized as Suzhou Innovative Famous and Excellent Product
In 2024, the company's product received recognition as an innovative product in Suzhou.
Company recognized as Jiangsu Innovative Small and Medium-sized Enterprise
In 2024, the company was recognized as an innovative SME in Jiangsu Province.